Rynek i konsumenci · 28.07.1995

Final Rule: Requirements for Child-Resistant Packaging; Packages Containing 250 mg or More of Naproxen

The Commission is issuing a rule to require child-resistant packaging for naproxen preparations containing 250 mg or more of naproxen per retail package. Naproxen is marketed as an anti- inflammatory drug. It is used to treat various forms of arthritis, mild to moderate pain, and menstrual pain. The Commission has determined that child-resistant packaging is necessary to protect children under 5 years of age from serious personal injury and serious illness resulting from ingesting naproxen. The Commission takes this action under the authority of the Poison Prevention Packaging Act of 1970.

Source: Federal Register — Consumer Product Safety CommissionOpen original release →

Find a company or service

Business Communicator helps companies present their offer, publish updates and connect directly.

Create a company profile Explore businesses on Business Maps →

LATEST SIGNALS

Rynek i konsumenci · 9/3/2026

Notice of Availability and Request for Comment: Revision to the Voluntary Standard for Products Containing Button Cell or Coin Batteries

The U.S. Consumer Product Safety Commission's (Commission or CPSC) mandatory rule, Safety Standard for Button Cell or Coin Batteries and Consumer Products Containing Such Products, incorporates by reference UL 4200A, Standard for Safety for Products Incorporating Button Batteries or Coin Cell Batteries. UL notified the Commission that it has revised this incorporated voluntary standard. CPSC seeks comment on whether the revision improves the safety of button cell or coin batteries and consumer products containing such products.

Read summary →

Rynek i konsumenci · 8/14/2026

Regulatory Agenda

In this document, the Commission publishes its regulatory flexibility agenda. Information in this agenda was accurate as of November 2025 when the Commission prepared this agenda.

Read summary →

Rynek i konsumenci · 8/6/2026

Johnson Health Tech

The Commission publishes in the Federal Register any settlement that it provisionally accepts under the Consumer Product Safety Act. Published below is a provisionally accepted Settlement Agreement with Johnson Health Tech., containing a civil penalty in the amount of $16,875,000, subject to the terms and conditions of the Settlement Agreement. The Commission provisionally accepts the proposed Settlement Agreement and Order pertaining to Johnson Health Tech.

Read summary →

Rynek i konsumenci · 7/23/2026

Removal of Obsolete or Unnecessary Requirements

The U.S. Consumer Product Safety Commission (Commission or CPSC) is reviewing its regulations to reduce regulatory burdens and costs. Pursuant to this review, CPSC has identified several obsolete or unnecessary provisions that are being removed or amended in this direct final rule. The changes in this rule will not affect consumer safety.

Read summary →

Rynek i konsumenci · 7/22/2026

Revocation of Obsolete Rules Regarding Infant Bouncer Seats and Stationary Activity Centers

The U.S. Consumer Product Safety Commission (Commission or CPSC) is reviewing its regulations to reduce regulatory burdens and costs. Pursuant to this review, CPSC has identified two rules concerning infant bouncer seats and stationary activity centers that are now obsolete because those products are subject to newer, more comprehensive mandatory safety standards issued by the Commission. This direct final rule removes the obsolete provisions to eliminate unnecessary duplication and improves regulatory clarity for manufacturers, testing laboratories, regulators, and the public. This action does not eliminate or reduce any mandatory federal safety standard applicable to infant bouncer seats or stationary activity centers. Both product categories will remain subject to the Commission's mandatory safety standards.

Read summary →

Rynek i konsumenci · 7/21/2026

Request for Comment: Commission Agenda and Priorities

The U.S. Consumer Product Safety Commission (Commission or CPSC) seeks public comment from interested parties about the Commission's agenda and priorities for fiscal year (FY) 2027, which begins October 1, 2026, and for FY 2028, which begins October 1, 2027.

Read summary →